Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone at ASCO 201...
Author: Annual-Meeting
Added: 06/04/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Rituxan